晚期卵巢癌新辅助化疗后间歇性肿瘤细胞减灭术预后获益相关因素分析
该回顾性研究纳入216例Ⅲc~Ⅳ期卵巢上皮性癌患者,比较PDS组(75例)与NACT+IDS组(141例)的预后。NACT+IDS组R0切除率更高但中位PFS更短,两组中位OS无显著差异。IDS前血清CA125正常及IDS后≤7天开始化疗是与预后获益相关的因素。
要点
- NACT+IDS组R0切除率61.7%高于PDS组41.3%,但中位PFS 9.1个月短于PDS组15.2个月。
- IDS前血清CA125正常和(或)IDS后≤7天开始化疗者PFS较长,达与PDS组相当水平。
- 术后残留灶大小是NACT+IDS组PFS和OS的独立影响因素。
核心结论
- IDS前血清CA125水平正常、IDS后不超过7天开始化疗是影响NACT+IDS治疗的晚期卵巢癌患者预后获益的相关因素。
研究设计与样本
- 回顾性分析2014年1月1日至2018年12月31日四川省肿瘤医院收治的Ⅲc~Ⅳ期卵巢上皮性癌患者216例,分为PDS组75例和NACT+IDS组141例。
主要发现
- NACT+IDS组中位PFS 9.1个月短于PDS组15.2个月(χ²=7.014,P=0.008),中位OS 42.6个月与PDS组38.0个月无显著差异(χ²=1.325,P=0.250)。
- 多因素分析显示BMI、术后残留灶大小、术后开始化疗时间是NACT+IDS组PFS独立因素(P<0.05);手术病理分期、IDS前血清CA125水平、术后残留灶大小是OS独立因素(P<0.05)。
- IDS前血清CA125正常和(或)IDS后≤7天开始化疗者PFS较长,达与PDS组相当水平,OS有延长趋势,但差异均无统计学意义(P>0.05)。
关键数值与推荐
- IDS前血清CA125水平正常、IDS后开始化疗时间≤7天。
- 力争在3个疗程左右使血清CA125水平降至正常再行IDS。
临床怎么用
- 及时调整NACT剂量和方案,争取约3个疗程使血清CA125降至正常后行IDS。
- 加强IDS围手术期管理,促进术后恢复,力争IDS后≤7天开始化疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the prognostic factors of patients with advanced epithelial ovarian cancer (EOC) who received neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). Methods: The clinical and pathological data of patients with stage Ⅲc-Ⅳ EOC underwent surgical treatment in Sichuan Cancer Center from January 1st, 2014 to December 31th, 2018 were retrospectively analyzed, and the prognosis was followed up. Results: (1) A total of 216 EOC patients were included in the study, whose age was (52.1±8.7) years old, the median follow-up time was 44.6 months (17.2-80.1 months), the median progression free survival (PFS) was 11.1 months (8.5-13.8 months), and the median overall survival (OS) was 40.0 months (32.7-47.3 months). (2) Among 216 patients with advanced EOC, there were 75 cases in the primary debulking surgery (PDS) group and 141 cases in the NACT+IDS group. Compared with the PDS group, the serum CA125 level before treatment (median: 859.4 vs 1 371.0 kU/L), proportion of stage Ⅳ patients [5.3% (4/75) vs 23.4% (33/144)] and no visible residual disease (R0) cytoreduction rate in the NACT+IDS group were significantly higher [(41.3% (31/75) vs 61.7% (87/144); all P<0.05]. The median PFS in the NACT+IDS group was significantly shorter than that of the PDS group (9.1 vs 15.2 months; χ2=7.014, P=0.008), but there was no significant difference in the median OS between the two groups (42.6 vs 38.0 months; χ2=1.325, P=0.250). (3) Univariate analysis showed that body mass index (BMI), preoperative serum CA125 level, surgical-pathological stage, NACT effect, postoperative residual tumor size, time to initiation of postoperative chemotherapy and chemotherapy regimen were significantly correlated with PFS in the NACT+IDS group (all P<0.05); preoperative serum CA125 level, surgical-pathological stage, NACT effect, postoperative residual tumor size, postoperative chemotherapy regimen were significantly related with OS in the NACT+IDS group (all P<0.05). Multivariate analysis showed that BMI, postoperative residual tumor size, time to initiation of postoperative chemotherapy were independent factors of PFS in the NACT+IDS group (all P<0.05); preoperative serum CA125 level, surgical-pathological stage, postoperative residual tumor size were independent factors of OS in the NACT+IDS group (all P<0.05). The results showed that the PFS of patients with normal preoperative serum CA125 level and (or) chemotherapy ≤7 days after IDS was longer, while no significant difference comparable with those in the PDS group (P>0.05), and OS was also showing an prolonged trend, but the difference was also not statistically significant (P>0.05). Conclusions: Normal CA125 before IDS and time received chemotherapy no longer than 7 days after IDS are two related factors of prognosis benefit in advance EOC patients treated with NACT+IDS. Therefore, timely adjustment of the dose and regimen of NACT to reduce CA125 level to normal range in about three cycles before IDS, and strengthen IDS perioperative management to promote postoperative recovery and perform chemotherapy as soon as possible might help to improve the prognosis of patients. 目的: 对接受新辅助化疗(NACT)+间歇性肿瘤细胞减灭术(IDS)治疗的晚期(Ⅲc~Ⅳ期)卵巢上皮性癌(卵巢癌)患者的预后获益及相关影响因素进行初步探索。 方法: 回顾性分析2014年1月1日至2018年12月31日在四川省肿瘤医院接受手术治疗的Ⅲc~Ⅳ期卵巢癌患者的临床病理资料及随访资料,根据治疗方式不同将患者分为初次肿瘤细胞减灭术(PDS)组(PDS+术后化疗)、NACT+IDS组(NACT+IDS+术后化疗),比较两组患者的预后,并对影响NACT+IDS组患者预后的相关因素进行单因素和多因素分析。 结果: (1)本研究共纳入216例晚期卵巢癌患者,其年龄为(52.1±8.7)岁,中位随访时间为44.6个月(17.2~80.1个月),中位无进展生存时间(PFS)为11.1个月(8.5~13.8个月),中位总生存时间(OS)为40.0个月(32.7~47.3个月)。(2)216例晚期卵巢癌患者中,PDS组75例,NACT+IDS组141例;与PDS组比较,NACT+IDS组患者的治疗前血清CA125水平(中位数分别为859.4、1 371.0 kU/L)、Ⅳ期患者比例[分别为5.3%(4/75)、23.4%(33/144)]、术后无肉眼可见残留灶(R0)切除率[分别为41.3%(31/75)、61.7%(87/141)]均显著增高(P<0.05)。NACT+IDS组患者的中位PFS显著短于PDS组(分别为9.1、15.2个月;χ²=7.014,P=0.008),但两组患者的中位OS比较无显著差异(分别为42.6、38.0个月;χ²=1.325,P=0.250)。(3)单因素分析显示,体质指数(BMI)、手术病理分期、NACT疗效、IDS前血清CA125水平、术后残留灶大小、术后开始化疗时间及化疗方案与NACT+IDS组患者的PFS显著相关(P<0.05);手术病理分期、NACT疗效、IDS前血清CA125水平、术后残留灶大小、术后开始化疗时间及化疗方案与NACT+IDS组患者的OS显著相关(P<0.05)。多因素分析显示,BMI、术后残留灶大小、术后开始化疗时间是影响NACT+IDS组患者PFS的独立因素(P<0.05);手术病理分期、IDS前血清CA125水平、术后残留灶大小是影响NACT+IDS组患者OS的独立因素(P<0.05)。进一步将本研究提示的影响NACT+IDS组患者PFS、OS的独立因素(分别为IDS前血清CA125水平正常、IDS后开始化疗时间≤7 d)进行分析,结果显示,IDS前血清CA125水平正常和(或)IDS后≤7 d开始化疗患者的PFS较长,达到与PDS组相当的水平,其OS也有延长的趋势,但分别与NACT+IDS组比较,差异均无统计学意义(P>0.05)。 结论: IDS前血清CA125水平正常、IDS后不超过7 d开始化疗是显著影响NACT+IDS治疗的晚期卵巢癌患者预后获益的相关因素。因此,及时调整NACT的剂量和方案,力争在3个疗程左右使血清CA125水平降至正常再行IDS,以及加强IDS围手术期管理,促进患者术后恢复以实现尽快化疗,可能有助于改善晚期卵巢癌患者的预后。.
引用
- Wang DF, Zhang GN, Peng CR, et al. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi. 2021. PMID: 34154313. doi:10.3760/cma.j.cn112141-20201207-00871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。